A chimeric IgG1 anti–TNF-α monoclonal antibody biosimilar to infliximab. Binds soluble and transmembrane TNF-α to block TNFR1/2 signaling and downstream NF-κB/MAPK pathways, reducing proinflammatory cytokines (e.g., IL-1, IL-6) and adhesion molecules; can induce apoptosis and Fc-mediated cytotoxicity of TNF-expressing immune cells. Administered subcutaneously (120 mg every 2 weeks) or intravenously (5–10 mg/kg every 8 weeks) for maintenance therapy in Crohn’s disease.